Momenta Pharmaceuticals Upgraded to “Hold” by TheStreet (MNTA)
Momenta Pharmaceuticals (NASDAQ:MNTA) was upgraded by equities researchers at TheStreet from a “sell” rating to a “hold” rating in a research report issued on Friday, Analyst Ratings Net reports.
The analysts wrote, “Momenta Pharmaceuticals (MNTA) has been upgraded by TheStreet Ratings from sell to hold. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company’s earnings per share, deteriorating net income and disappointing return on equity.”
A number of other analysts have also recently weighed in on MNTA. Analysts at R. F. Lafferty initiated coverage on shares of Momenta Pharmaceuticals in a research note to investors on Monday, October 14th. They set a “buy” rating and a $19.00 price target on the stock. Analysts at Canaccord Genuity raised their price target on shares of Momenta Pharmaceuticals from $13.00 to $22.00 in a research note to investors on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Momenta Pharmaceuticals has a consensus rating of “Buy” and an average price target of $18.17.
Momenta Pharmaceuticals (NASDAQ:MNTA) traded down 1.56% during mid-day trading on Friday, hitting $16.43. The stock had a trading volume of 259,443 shares. Momenta Pharmaceuticals has a 52-week low of $10.05 and a 52-week high of $18.08. The stock’s 50-day moving average is $15.51 and its 200-day moving average is $14.10. The company’s market cap is $834.9 million.
Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Thursday, August 1st. The company reported ($0.57) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.45) by $0.12. The company had revenue of $4.40 million for the quarter, compared to the consensus estimate of $8.85 million. During the same quarter in the prior year, the company posted ($0.20) earnings per share. The company’s quarterly revenue was down 79.9% on a year-over-year basis. On average, analysts predict that Momenta Pharmaceuticals will post $-1.99 earnings per share for the current fiscal year.
Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.